Petrioli R, et al. - In this investigation, researchers assessed the effectiveness and safety of the combination of CAPOX-Bev (capecitabine [Cap] plus oxaliplatin and bevacizumab [Bev]), followed by maintenance Cap and Bev, for patients with metastatic colorectal cancer (mCRC) and aged > 75 years. The regimen consisted of 130 to 100 mg/m² intravenous oxaliplatin on day 1, oral Cap 750 to 1000 mg/m² twice daily on days 1 to 14, and Bev 7.5 mg/kg on day 1, every 3 weeks. Among 36 patients who were recruited from March 2012 to April 2017, CAPOX/Bev is safe and effective with regard to progression-free survival (PFS) and overall survival (OS) for elderly patients aged > 75 years with mCRC, followed by Cap/Bev as maintenance treatment. The most common grade 3 toxicity included neutropenia, diarrhea, nausea/vomiting, and fatigue with the CAPOX/Bev regimen.